Ipamorelin — Uses, Evidence, and Regulatory Status

Editorial caution Compounded — not FDA-approved. This page is an editorial overview, not medical advice or a recommendation. Many peptides have limited human-trial evidence. Always work with a licensed, board-certified clinician.

What it is

Ipamorelin is a selective growth hormone secretagogue. Prompts pulsatile GH release without the cortisol or appetite spikes seen with older GHRPs.

Mechanism of action

Ipamorelin is a synthetic pentapeptide and selective ghrelin receptor (GHSR-1a) agonist that stimulates pulsatile growth hormone (GH) release from the pituitary. Unlike older growth-hormone secretagogues (GHRP-2, GHRP-6), ipamorelin selectively binds the GH-release pathway without significantly affecting cortisol, prolactin, or appetite. This selectivity is the primary advantage.

Reported uses

Adult growth hormone optimization: Used in anti-aging and longevity-medicine clinics to support endogenous GH levels in middle-aged and older adults.
Sleep quality: Subjective improvement in sleep depth and recovery is commonly reported, consistent with the natural relationship between sleep and pulsatile GH release.
Recovery and body composition: Reported benefit for training recovery and lean-mass retention. Direct evidence is limited.
Often combined with CJC-1295: The standard ipamorelin protocol pairs the two peptides for additive GH-release effects.

Evidence base

Limited human trials; well-studied in animal models and small Phase II programs.

Regulatory status

Compounded — not FDA-approved.

Typical dosing context

Common protocols:

Standalone: 200–300 mcg subcutaneous, 1–3 times daily. Most commonly dosed before bed to leverage natural overnight GH pulse.
With CJC-1295 (no DAC): Most common stack. Combined dose often 200/100 mcg or 300/200 mcg (ipamorelin/CJC-1295) before bed.
With CJC-1295 (with DAC): Less common; the long-acting DAC form provides sustained stimulation.
Cycle length: 8–12 weeks on with breaks, though some protocols run continuously.

Dosing in research and clinical-use contexts varies. Specific protocols should always be set by a prescribing clinician, not by patient-direct sources.

Side effects and safety

Generally well-tolerated. Reported side effects: injection-site irritation, transient water retention, mild fatigue in the first week, occasional headaches. Long-term safety of GH secretagogue use is not well-studied; theoretical concerns include effects on glucose metabolism and the same theoretical cancer-promotion concerns as exogenous HGH (though ipamorelin only stimulates physiologic GH release, not exogenous administration).

Common stacking protocols

The standard stack is ipamorelin + CJC-1295 (with or without DAC) for additive GH release. Patients pursuing recovery often add BPC-157 + TB-500 for tissue-repair effects. Tesamorelin can substitute for CJC-1295 in patients prioritizing visceral fat reduction.

How to access Ipamorelin

Most peptides discussed on this page are compounded products requiring a prescription from a licensed clinician. Reputable telehealth peptide programs include physician-led oversight, accredited compounding pharmacies, and clear regulatory framing. For weight-management GLP-1 programs, see our provider reviews.

Frequently asked questions

What is Ipamorelin?

Ipamorelin is a selective growth hormone secretagogue. Prompts pulsatile GH release without the cortisol or appetite spikes seen with older GHRPs.

Is Ipamorelin FDA-approved?

Compounded — not FDA-approved.

What are the typical uses of Ipamorelin?

Uses include: GH support, Recovery, Sleep quality (research). This is research and clinical-use context, not a recommendation. Always work with a licensed clinician.

What is the evidence behind Ipamorelin?

Limited human trials; well-studied in animal models and small Phase II programs.

What is the typical dosing for Ipamorelin?

Reported dosing: 200–300 mcg subcutaneous before bed, often paired with CJC-1295. Actual dosing should always be determined by your prescribing clinician, not by online sources.

Is ipamorelin the same as HGH?

No. Ipamorelin stimulates your own pituitary to release endogenous GH in physiologic pulses. Exogenous HGH is administered as the hormone itself, producing sustained supraphysiologic levels. The risk profiles are different.

Will it make me bigger?

Modest effects on lean-mass retention and fat reduction are reported, but ipamorelin is not a 'bulking' compound. Effects are subtle and cumulative over months.

How long until I notice effects?

Sleep effects often within the first 1–2 weeks. Body composition and recovery effects build over 8–12 weeks.

Related peptides

BPC-157 TB-500 NAD+ PT-141 Ipamorelin CJC-1295 All peptides